Crizotinib

Crizotinib treatment effective against ROS1-positive lung cancer

By

Treatment with the drug crizotinib has been effective for stopping lung tumor growth driven by rearrangements of the ROS1 gene.

'Weeding the garden' technique extends effectiveness of crizotinib for NSCLC

By

Patients taking crizotinib for ALK-positive non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.

Redefining the criteria for ALK-positive lung cancer

By

The current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug. A new study suggests that doctors should look closer at borderline or atypical ALK-negative cases.

Trial results demonstrate superiority of crizotinib for ALK-positive NSCLC

By

Crizotinib is superior to standard chemotherapy for treating advanced ALK-positive non-small cell lung cancer, according to the final results of a global, phase III trial.

Targeted treatment of resistant cancer may improve progression-free survival with some drugs

By

Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.

Managing side effects of crizotinib

By

What specific visual changes are associated with the new drug crizotinib and what causes them?

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs